Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation by James N. Kochenderfer,

Slides:



Advertisements
Similar presentations
Kochenderfer JN et al. Proc ASH 2013;Abstract 168.
Advertisements

Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26
The Role of Immunotherapy for the Treatment of Hematologic Malignancies Patrick Stiff MD Coleman Professor of Oncology Loyola University Medical Center.
Retrovirally Transduced CD34++ Human Cord Blood Cells Generate T Cells Expressing High Levels of the Retroviral Encoded Green Fluorescent Protein Marker.
Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.
Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host.
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell–depleted hematopoietic stem cell transplantation and.
by Jane Yui, Choy-Pik Chiu, and Peter M. Lansdorp
Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism  Gerald A. Colvin, David Berz, Muthalagu.
Gene transfer into hematopoietic stem cells reduces HLH manifestations in a murine model of Munc13-4 deficiency by Tayebeh Soheili, Amandine Durand, Fernando.
Volume 19, Issue 12, Pages (December 2011)
by Lianne van de Laar, Aniek van den Bosch, André Boonstra, Rekha S
Two cases of disseminated Mycobacterium avium infection associated with a new immunodeficiency syndrome related to CXCR4 dysfunctions  A.-V. Doncker,
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.
Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes
Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.
Volume 19, Issue 3, Pages (March 2011)
by Marlène Brandes, Katharina Willimann, Alois B
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Volume 137, Issue 3, Pages e7 (September 2009)
Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome by Junji Xu, Dandan Wang, Dayong Liu, Zhipeng Fan, Huayong.
by Éric Aubin, Réal Lemieux, and Renée Bazin
Role of IL-9 in the pathophysiology of allergic diseases
Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells by Sergey Krysov, Samantha Dias, Alex Paterson, C.
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.
Volume 138, Issue 5, Pages e2 (May 2010)
Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.
Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen.
Volume 25, Issue 10, Pages (October 2017)
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation 
Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host.
LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis by Albert Gutierrez,
Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences.
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function by Vânia Coelho, Sergey Krysov, Andrew.
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach  Jeremiah.
Volume 138, Issue 4, Pages (April 2010)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results by Brian.
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies by Julie Gertner-Dardenne, Cecile Bonnafous,
Volume 25, Issue 3, Pages (March 2017)
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Volume 25, Issue 8, Pages (August 2017)
CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis  Esther Morel, PhD, Salvador Escamochero,
Volume 4, Issue 2, Pages (February 2003)
Lisa A. Palmer, George E. Sale, John I
Quantity and Quality Reconstitution of NKG2A+ Natural Killer Cells Are Associated with Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation 
Volume 18, Issue 4, Pages (April 2010)
Volume 23, Issue 4, Pages (April 2015)
Volume 16, Issue 6, Pages (June 2008)
Volume 24, Issue 9, Pages (September 2016)
Volume 43, Issue 2, Pages (August 2015)
Volume 25, Issue 11, Pages (November 2017)
Volume 16, Issue 2, Pages (July 2016)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies  David Halverson,
by Hakan Köksal, Pierre Dillard, Sarah E
Volume 24, Issue 6, Pages (June 2016)
Volume 21, Issue 11, Pages (November 2013)
Senescence-associated defective HLA-DR upregulation does not modulate immunosuppressive properties of MSCs. (A) Fit and senescent MSCs were subjected to.
by Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F
Targeting CD47 in Sézary syndrome with SIRPαFc
Volume 21, Issue 4, Pages (April 2013)
ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.
The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α,
CD123 CAR T cells for the treatment of myelodysplastic syndrome
Presentation transcript:

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation by James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter, Sadik H. Kassim, Jeremy J. Rose, William G. Telford, Frances T. Hakim, David C. Halverson, Daniel H. Fowler, Nancy M. Hardy, Anthony R. Mato, Dennis D. Hickstein, Juan C. Gea-Banacloche, Steven Z. Pavletic, Claude Sportes, Irina Maric, Steven A. Feldman, Brenna G. Hansen, Jennifer S. Wilder, Bazetta Blacklock-Schuver, Bipulendu Jena, Michael R. Bishop, Ronald E. Gress, and Steven A. Rosenberg Blood Volume 122(25):4129-4139 December 12, 2013 ©2013 by American Society of Hematology

An anti-CD19 CAR gives T cells the ability to specifically recognize CD19. An anti-CD19 CAR gives T cells the ability to specifically recognize CD19. (A) The CAR incorporated an anti-CD19 single chain Fv (scFv), part of the CD28 costimulatory molecule, and the cytoplasmic part of the CD3ζ molecule. (B) PBMCs from healthy allogeneic donors were activated with an anti-CD3 monoclonal antibody and transduced with gammaretroviruses encoding an anti-CD19 CAR. The cells were infused after 8 days of culture. (C) Expression of the CAR was detected on the surface of the infusion cells of patient 1 on day 7 of culture by staining with anti–antigen-binding fragment (Fab) antibodies. Staining with isotype-matched control antibodies is also shown. The plots are gated on CD3+ lymphocytes. (D) The infusion cells of patient 1 were stained for CD45RA and CC chemokine receptor 7 (CCR7). Staining with isotype-matched control antibodies is also shown. The staining was performed on day 7 of culture, and the plots are gated on CAR-expressing CD3+ lymphocytes. (E) On day 8 of culture, infusion cells of patient 1 were cultured for 4 hours with either the CD19+ cell line CD19-K562 or the negative-control cell line NGFR-K562 that does not express CD19. CD19-specific upregulation of CD107a occurred. Plots are gated on CD3+ lymphocytes. Similar results were obtained with the infusion cells of all patients treated. (F-H) A representative example of CD19-specific cytokine production by anti-CD19-CAR T cells is shown. Infusion cells of patient 4 were stimulated with either CD19-K562 cells or NGFR-K562 cells for 6 hours on day 8 of culture. Intracellular cytokine staining followed by flow cytometry revealed that large fractions of the T cells produced interferon γ (IFN-γ), tumor necrosis factor (TNF), and interleukin (IL) 2 in a CD19-specific manner. Plots are gated on CD3+ lymphocytes. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

Tumor lysis syndrome and regression of adenopathy occurred after infusion of allogeneic anti-CD19-CAR T cells into patient 1. Tumor lysis syndrome and regression of adenopathy occurred after infusion of allogeneic anti-CD19-CAR T cells into patient 1. (A) Serum lactate dehydrogenase (LDH) levels increased after the CAR-transduced T-cell infusion and then decreased as toxicity resolved. (B) The serum uric acid was 5.4 mg/dL (normal range 3.7-8.6 mg/dL) before the CAR T-cell infusion. Eight days after the infusion, the serum uric acid increased sharply before the recombinant urate oxidase drug rasburicase was given to reduce the uric acid. (C) Shortly after infusion of anti-CD19-CAR T cells, the total blood lymphocyte count abruptly decreased and then recovered to normal levels. (D) Serum IFN-γ levels at the indicated days after anti-CD19-CAR T-cell infusion were determined by enzyme-linked immunosorbent assay. A transient increase in serum IFN-γ occurred during the period of clinical toxicity. (E) CT scans were performed before the anti-CD19-CAR T-cell infusion and 26 days after the anti-CD19-CAR T-cell infusion. A decrease in adenopathy occurred at the locations indicated by the arrows. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

A profound eradication of CLL cells from the bone marrow and blood occurred after infusion of anti-CD19-CAR T cells into patient 1. A profound eradication of CLL cells from the bone marrow and blood occurred after infusion of anti-CD19-CAR T cells into patient 1. (A) A bone marrow biopsy was performed 2 days before anti-CD19-CAR T cells were infused. Bone marrow immunohistochemistry staining showed that 80% to 90% of the bone marrow cells consisted of atypical lymphoid cells that had a morphology consistent with CLL. The atypical lymphoid cells were CD79a+ and CD19+. Flow cytometry staining for immunoglobulin light chain restriction showed that the cells were clonal (not shown). (B) Twenty-six days after the anti-CD19-CAR T-cell infusion, immunohistochemistry staining of a bone marrow specimen showed no morphologic evidence of CLL. Only rare CD79a+ cells were present. (C) Blood B cells, of which 99% were CLL cells, dropped dramatically after infusion of anti-CD19-CAR T cells. (D) Patient 1 was dependent on platelet transfusions before the infusion of anti-CD19-CAR T cells. After the CAR T-cell infusion, the patient no longer required platelet transfusions. His platelet count increased for ∼2 months after the anti-CD19-CAR T-cell infusion; subsequently, his platelet count decreased when his CLL progressed. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

Patient 5 obtained a CR after infusion of anti-CD19-CAR T cells. Patient 5 obtained a CR after infusion of anti-CD19-CAR T cells. (A) Within 9 days after infusion of anti-CD19-CAR T cells, B cells were eradicated from the blood of patient 5. T cells (B) and NK cells (C) were at normal levels in the blood of patient 5 at the time of anti-CD19-CAR T-cell infusion. T-cell levels remained in the normal range, whereas NK cell levels fluctuated. The dashed line on the plots in panels A-C is the lower limit of the normal range of each cell type. (D) CT scans show that abdominal adenopathy regressed in patient 5 after infusion of anti-CD19-CAR T cells. The red arrows indicate a lymph node mass that regressed to a normal-sized lymph node. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

Regression of adenopathy in patient 9 within 1 month after anti-CD19-CAR T-cell infusion. Regression of adenopathy in patient 9 within 1 month after anti-CD19-CAR T-cell infusion. CT scans before the cell infusion (A) and after infusion of anti-CD19-CAR T cells showing that mediastinal adenopathy had regressed in patient 9 (B). The red arrows indicate a lymph node mass that regressed. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

Anti-CD19-CAR–expressing T cells were detected in the blood of patients. Anti-CD19-CAR–expressing T cells were detected in the blood of patients. (A) qPCR was used to determine the percentage of total PBMCs that contained the anti-CD19-CAR gene. The highest percentages of PBMCs containing the CAR gene were generally found between 6 and 14 days after infusion. (B) The absolute number of PBMCs containing the CAR gene per microliter of blood was determined by qPCR. (C) PBMCs from patient 8 were stained with a CAR-specific monoclonal antibody. Pretreatment PBMCs and PBMCs from 9 days after infusion were stained. Most CAR+ cells detected 9 days after infusion were CD4+. (D) PBMCs from patient 9 were stained with a CAR-specific monoclonal antibody. Pretreatment PBMCs and PBMCs from 7 days after infusion were stained. CAR+ cells included both CD4+ and CD8+ T cells. The plots in panels C and D are gated on live CD3+ lymphocytes. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology

Phenotype of anti-CD19-CAR–expressing T cells. Phenotype of anti-CD19-CAR–expressing T cells. (A) Infusion cells of patient 5 are shown after staining with a CAR-specific antibody. The first plot is gated on CD3+CD8+ cells. The phenotype of the CD3+CD8+CAR+ cells is shown on the subsequent plots of CD45RA vs CCR7, programmed cell death protein 1 (PD-1) vs CD57, and CD27 vs CD28. (B) CAR expression was assessed on pretreatment lymphocytes of patient 5 by flow cytometry. The plot shows minimal background staining when the cells were stained with a CAR-specific monoclonal antibody. The plot is gated on CD3+CD8+ lymphocytes. (C) The first plot is gated on CD3+CD8+ lymphocytes that were obtained from patient 5 12 days after CAR T-cell infusion. CAR+ cells made up 2.2% of the CD3+CD8+ lymphocytes. The subsequent CD45RA vs CCR7, PD-1 vs CD57, and CD27 vs CD28 plots are gated on CD3+CD8+ lymphocytes that are either CAR+ or CAR–. (D) Infusion cells of patient 5 are shown. The first plot is gated on CD3+CD4+ cells. Subsequent plots show the phenotype of CD3+CD4+CAR+ cells. (E) The plot shows minimal background staining when pretreatment lymphocytes from patient 5 were stained with a CAR-specific antibody. The plot is gated on CD3+CD4+ lymphocytes. (F) The first plot is gated on CD3+CD4+ lymphocytes that were obtained from patient 5 12 days after CAR T-cell infusion. CAR+ cells made up 7.4% of the CD3+CD4+ lymphocytes. Subsequent plots show the phenotype of CD3+CD4+ cells that were either CAR+ or CAR–. Increased expression of the T-cell inhibitory protein PD-1 was present on CD4+CAR+ T cells (G) and CD8+CAR+ T cells (H) relative to CAR– T cells from the same patient at the time of the peak in the level of CAR+ blood T cells in each patient. The percentage of PD-1+ T cells is shown for the CAR+ and CAR– T cells of the indicated patients. Note that an insufficient number of CAR+CD8+ T cells were present in the blood of patient 10 to allow accurate determination of PD-1–expressing CD8+ cells in this patient. PD-1 expression was determined as shown in panels C and F. For CD4+ T cells, the difference in PD-1 expression between CAR+ cells and CAR– cells was statistically significant (P = .03, Mann-Whitney U test). PD-1 levels are only shown for 4 patients because some patients had very low or undetectable levels of CAR+ T cells in their blood and because we lacked sufficient PBMCs from relevant time points to conduct the experiment in some other patients. James N. Kochenderfer et al. Blood 2013;122:4129-4139 ©2013 by American Society of Hematology